| 引用本文: | 罗玉,尹向楠,徐强,王涛.高尿酸血症的炎症机制及药物研发策略[J].药学研究,2025,44(11):1,119-11,271,144[点击复制] |
|
| 摘要: |
| 高尿酸血症(HUA)是痛风、代谢综合征及心血管疾病的独立危险因素,全球成人患病率高达16%~20%。近年研究揭示,炎症在HUA病理进程中占据核心地位,通过激活NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎症小体触发白介素-1β(IL-1β)释放,启动先天免疫应答;树突状细胞进一步介导辅助性T细胞17/调节性T细胞失衡,放大适应性免疫炎症级联。同时,部分炎症因子通过上调黄嘌呤氧化酶活性、抑制尿酸排泄形成“尿酸-炎症”恶性循环,加重器官损伤。传统降尿酸药物虽可控制血尿酸水平,但无法阻断炎症通路,而靶向NLRP3通路抑制剂、兼具抗炎/降尿酸双重功能药物(如改良非甾体抗炎药)及代谢调控策略为治疗HUA提供新方向。解析炎症-代谢交互网络,是开发HUA精准疗法的关键。 |
| 关键词: 高尿酸血症 炎症 先天免疫细胞 辅助性T细胞17/调节性T细胞 炎症因子 |
| DOI:10.13506/j.cnki.jpr.2025.11.012 |
| 基金项目: |
|
出版日期:2025-11-25
|
|
| Inflammatory mechanisms of hyperuricemia and strategies for drug development |
| LUO Yu,YIN Xiangnan,XU Qiang,WANG Tao |
| (State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China) |
| Abstract: |
| Hyperuricemia (HUA) is an independent risk factor for gout, metabolic syndrome, and cardiovascular diseases, with a global adult prevalence rate of 16%-20%. Recent studies have revealed that the inflammatory plays a central role in the pathological process of HUA. It triggers the release of IL-1β by activating the NLRP3 inflammasome, initiating the innate immune response; dendritic cells (DCs) further mediate the Th17/Treg imbalance, amplifying the adaptive immune inflammatory cascade. Meanwhile, inflammatory cytokines (such as IL-1β, TNF-α) up-regulate the activity of xanthine oxidase and inhibit uricosuria, forming a vicious cycle of "urate-inflammation", which exacerbates organ damage. Although traditional urate-lowering drugs can control serum uric acid levels, they cannot block the inflammatory pathway. Targeted NLRP3 pathway inhibitors, drugs with dual anti-inflammatory/uricosuric functions (such as modified NSAIDs), and metabolic regulation strategies provide new directions for treatment. Analyzing the inflammation-metabolism interaction network is key to developing precise therapies for HUA. |
| Key words: Hyperuricemia Inflammation Innate immune cells Th17/Treg and inflammatory cytokines |